Related Experiment Videos
In situ assembly of enzyme inhibitors using extended tethering
Daniel A Erlanson1, Joni W Lam, Christian Wiesmann
1Sunesis Pharmaceuticals, Inc., 341 Oyster Point Boulevard, South San Francisco, CA 94080, USA. erlanson@sunesis.com
Nature Biotechnology
|February 4, 2003
Summary
Researchers developed novel small-molecule inhibitors for caspase-3, a key apoptosis mediator. This new approach yielded a potent inhibitor that successfully reduced apoptosis in cellular studies, offering therapeutic potential.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- Caspase-3 is a critical enzyme in apoptosis, making it a significant therapeutic target for various diseases.
- Existing caspase-3 inhibitors often lack specificity or desired drug-like properties.
Purpose of the Study:
- To identify novel, nonpeptidic inhibitors for caspase-3 using an innovative dynamic combinatorial technology.
- To develop small-molecule inhibitors that bind to distinct regions of caspase-3 and can be assembled into potent therapeutic agents.
Main Methods:
- Utilized 'extended tethering,' a dynamic combinatorial technology, to identify ligands for caspase-3.
- Designed a small-molecule 'extender' to alkylate caspase-3's cysteine residue, creating a modified protein.
- Screened the modified protein against a library of disulfide-containing fragments using mass spectrometry to identify binding ligands.
Main Results:
- Identified unique nonpeptidic ligands that bind to discrete sites on caspase-3.
- Assembled these ligands with the extender to create novel small-molecule inhibitors.
- One derived molecule demonstrated potent inhibition of apoptosis in cellular models and exhibited druglike properties.
Conclusions:
- Extended tethering is an effective strategy for discovering unique, nonpeptidic inhibitors for caspase-3.
- The developed inhibitors are distinct from known compounds and show promise for therapeutic applications in diseases involving apoptosis.